Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Assets (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Current Assets for 10 consecutive years, with $192.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 49.04% to $192.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $192.7 million through Dec 2025, down 49.04% year-over-year, with the annual reading at $192.7 million for FY2025, 49.04% down from the prior year.
  • Current Assets hit $192.7 million in Q4 2025 for Rocket Pharmaceuticals, down from $227.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $471.8 million in Q1 2021 to a low of $192.7 million in Q4 2025.
  • Historically, Current Assets has averaged $341.5 million across 5 years, with a median of $341.6 million in 2023.
  • Biggest five-year swings in Current Assets: soared 82.27% in 2021 and later plummeted 49.04% in 2025.
  • Year by year, Current Assets stood at $392.1 million in 2021, then fell by 7.14% to $364.1 million in 2022, then grew by 3.89% to $378.2 million in 2023, then decreased by 0.01% to $378.2 million in 2024, then tumbled by 49.04% to $192.7 million in 2025.
  • Business Quant data shows Current Assets for RCKT at $192.7 million in Q4 2025, $227.7 million in Q3 2025, and $277.2 million in Q2 2025.